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Abstract: Oligomycin-A (Oli-A), an anticancer drug, was loaded to the folate (FA)-conjugated 
chitosan as a tumor-targeted drug delivery system for the purpose of overcoming the nonspe-
cific targeting characteristics and the hydrophobicity of the compound. The two-level factorial 
design (2-LFD) was applied to modeling the preparation process, which was composed of 
five independent variables, namely FA-conjugated chitosan (FA-CS) concentration, Oli-A 
concentration, sodium tripolyphosphate (TPP) concentration, the mass ratio of FA-CS to TPP, 
and crosslinking time. The mean particle size (MPS) and the drug loading rate (DLR) of the 
resulting Oli-loaded FA-CS nanoparticles (FA-Oli-CSNPs) were used as response variables. 
The interactive effects of the five independent variables on the response variables were studied. 
The characteristics of the nanoparticles, such as amount of FA conjugation, drug entrapment rate 
(DER), DLR, surface morphology, and release kinetics properties in vitro were investigated. 
The FA-Oli-CSNPs with MPS of 182.6 nm, DER of 17.3%, DLR of 58.5%, and zeta potential 
(ZP) of 24.6 mV were obtained under optimum conditions. The amount of FA conjugation was 
45.9 mg/g chitosan. The FA-Oli-CSNPs showed sustained-release characteristics for 576 hours 
in vitro. The results indicated that FA-Oli-CSNPs obtained as a targeted drug delivery system 
could be effective in the therapy of leukemia in the future.
Keywords: oligomycin-A, chitosan, folate, targeted drug delivery system, nanoparticles, 
two-level factorial design
Introduction
Oligomycins are macrolides created by Streptomyces diastatochromogenes that can be 
poisonous to other organisms. They are found in four isomers, namely A, B, C, and D, 
and are highly specific for the disruption of mitochondrial metabolism, observed both 
in vitro and in vivo.1–4 Oligomycin A (Oli-A) (C45H74O11), a dominant analog of the 
isomers, is an inhibitor of mitochondrial F1F0-ATPase. It could induce apoptosis 
in a variety of cell types, make cells more susceptible to cell death and also lead to 
a switch in the death mode from apoptosis to necrosis. Oli-A exhibits a broad bio-
logical profile including antifungal, antitumor, and nematocidal activities. Scientists 
discovered that Oli-A could lead the chronic myelogenous leukemia (CML) cell to 
apoptosis.5   Unfortunately, Oli-A has poor solubility in water and other biocompatible 
solvents, which limits its clinical application. Moreover, Oli-A has no active targeting 
to the CML cell with lower treatment efficiency. Therefore, development of new drug 
delivery system for Oli-A has more prospects.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The use of chemotherapy to treat cancers is often 
  limited by unwanted toxic effects on normal tissues. This 
is because most anticancer drugs are not distributed in the 
target tumor-bearing tissues specifically, which results in 
reduced therapeutic efficacy. Therefore, it is evident that 
targeted delivery of anticancer drugs into the tumor tissue is 
the focus of intensive research to improve chemotherapy.6 
For this reason, various drug delivery systems have been 
investigated to reduce toxicity and increase the therapeutic 
efficacy of anticancer drugs.7 Targeting drug delivery system 
is a dosage system which promises to expand the therapeutic 
windows of drugs by increasing delivery to the target tissue 
as well as the target-non-target tissue ratio. This will in turn 
lead to a reduction in the minimum effective dose of the drug 
and the accompanying drug toxicity, and an improvement 
in therapeutic efficacy at equivalent plasma concentrations. 
Among targeting agents directed to membrane-bound tumor-
associated receptors, folate (FA) has been widely utilized as 
a ligand for FA receptor-mediated selective targeting and 
delivery of drugs into tumor cells.8 FA is potentially superior 
to antibodies as a targeting ligand because of its small size, 
lack of immunogenicity, ready availability, and simple and 
defined conjugation chemistry.9 The FA receptor is a tumor 
marker over expressed in more than 90% of ovarian carcino-
mas and large percentages of other human tumors, including 
acute myelogenous leukemia.10 Meanwhile, normal tissue 
distribution of the FA receptor is highly restricted, making it a 
useful marker for targeted drug delivery to tumors.11 Recently, 
it has been reported that FA-mediated delivery of drug-loaded 
nanoparticles can enable binding, promote uptake, and have 
increased cytoxicity to cancer cells in vitro and in vivo.12–14 For 
example, the nanoparticles of FA-conjugated water insoluble 
paclitaxel-loaded bovine serum albumin have shown natural 
property, high stability, desired surface properties in favor 
of cellular uptake, and can be targeted specifically to cancer 
cells compared to nanoparticles without FA conjugation.15 
Therefore, beneficial effects of nanoparticles targeting are 
likely found at the cellular and subcellular levels.
Chitosan (CS) is a biodegradable polysaccharide derived 
by partial deacetylation of chitin, which is a copolymer of 
glucosamine and N-acetyl-d-glucosamine linked together by 
β (1, 4) glycosidic bonds mainly from renewable crustacean 
shells, such as crab, shrimp, and squid pen. CS has been 
widely used as a drug carrier in pharmaceutical and medical 
areas, due to its favorable biopharmaceutical properties 
such as biocompatibility, biodegradability, and low toxicity 
properties.16–21 Thus, CS has been investigated as a carrier 
for gene therapy as well.22,23 In the theory of the pharmacy, 
the CS molecule is positive in acidic conditions due to 
containing amidocyanogen, it can be agglomerated by using 
ionic gelation with abundant negative charge, such as sodium 
tripolyphosphate (TPP), and form nanoparticles. In recent 
years, hollow nanospheres of CS have attracted considerable 
attention, because of their wide applications, such as optical, 
magnetic, and controlled drug-delivery carriers.24,25
In this study, we used CS as a carrier and FA as a target 
to produce active targeting preparations (oligomycin-loaded 
FA-conjugated-CS nanoparticles (FA-Oli-CSNPs)) with 
the purpose of developing a suitable targeted drug delivery 
system for CML chemotherapy. Moreover, the obtained FA-
Oli-CSNPs were characterized by particle size, zeta poten-
tial (ZP), amount of FA conjugation, drug entrapment rate 
(DER), drug loading rate (DLR), and surface morphology. 
The release kinetics properties in vitro were also tested.
Materials and methods
Materials
Oli-A (purity = 98.5%) was kindly provided by Hisun 
(Hisun Pharmaceutical Co, Ltd, Zhejiang, China). 
CS with 98.27% deacetylation degree and 67000 D viscos-
ity average molecular weight was purchased from Haidebei 
(Haidebei Marine Bioengineering Co, Ltd, Jinan, China), 
and needed a further purification process before using. FA 
(purity .98%) was obtained from Sigma (Sigma Aldrich, 
St Louis, MO). TPP (purity .99.5%) was purchased from 
Xi Long (Xi Long Chemical Factory, Shantou, Guangdong, 
China). N-hydroxysuccinimide (NHS, purity .99.0%), 1,3-
dicyclohexyl-carbodiimide (DCC, purity .95.0%), trieth-
ylamine (TEA, purity .99.5%), dimethyl sulfoxide (DMSO, 
purity .99.5%), phosphate-buffered solution (PBS, 0.15 
M, pH = 7.2–7.6), ethanol, and ether were analytical grade. 
Methanol and acetonitrile were HPLC grade.
Methods
Preparation of FA-Oli-csNPs
Preparation of the N-hydroxysuccinimide  
ester of FA (Nhs-FA)
The preparation procedure of NHS-FA was optimized after 
consulting the literature.26 In short, 3 g of FA was dissolved 
in 60 mL DMSO containing 1.5 mL TEA; this was followed 
by the addition of 2.82 g DCC and 1.56 g NHS. The mixture 
was stirred for 12 hours at room temperature; the insoluble 
side product dicyclohexylurea was removed by filtration, the 
filtrate was then poured into an ice-cold anhydrous ether solu-
tion containing 30% acetone, centrifuged, and washed twice. 
Finally, NHS-FA, a delicate light yellow solid powder, was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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obtained by drying at room temperature. The structure of 
NHS-FA was proved by FTIR spectroscopy detection.
Preparation of FA-conjugated cs (FA-cs)  
and the UV absorption spectroscopy of FA-cs
Before the preparation of FA-CS, the purification of CS was 
carried out. CS is a cationic polysaccharide. It is soluble at 
pH ,7 and insouluble at pH .7. The purification process is 
referred to in the literature.27 NHS-FA (1.50 g) was dissolved 
in DMSO (150 mL). The adequate dissolution process was 
performed in an ultrasonication bath TI-H-5 (Elma,   Singen, 
Germany). Thereafter, CS (1.00 g) was added into the DMSO-
containing NHS-FA, and stirred for 4 hours at 60°C. The 
reactant was deposited after centrifugating (12,000 rpm, 
5 min) at room temperature, and free NHS-FA was washed 
off by DMSO. Finally, the product was washed with deion-
ized water to remove residual DMSO and FA-CS was gained 
by freeze-drying.
The amount of NHS-FA conjugated with CS was evalu-
ated using the UV absorption spectroscopy technology. 
FA-CS (50 mg) was dissolved in 1% glacial acetic acid 
(50 mL). Then, the solution was scanned in the range of 200 
to 500 nm by UV-spectrophotometer (SHIMADZU, Tokyo, 
Japan), using the 1% acetic acid solution dissolving CS as a 
blank control. The amount of NHS-FA conjugated with CS 
was the mean of triplicate experiments.
Preparation and optimization of FA-Oli-csNPs  
by two-level factorial design (2-LFD)
FA-Oli-CSNPs were prepared by the ion crosslink method. 
The FA-CSNPs loading Oli-A were obtained from the supra-
molecular self-organizing interaction between the negatively 
charged TPP and the positively charged polysaccharide CS, 
without preliminary vesicle formation.28 As illustrated in 
Figure 1, briefly, after FA-CS was first dissolved in 1% acetic 
acid solution, ethanol dissolving Oli-A was added. The pH of 
the reaction system was adjusted to 5.4 with sodium hydrox-
ide (1 mol/L). Thereafter, the TPP solution was added with 
a peristaltic pump TI/62/20 (Medorex, Norten-Hardenberg, 
Germany) (4 mL/min) at room temperature. The reaction 
process was performed under magnetic stirring for a prede-
termined time period.
The mixture was centrifuged (10,000 rpm, 5 min) at 
25°C to separate the dissociative Oli-A from the superna-
tant, and was washed with 70% ethanol three times. The 
supernatant was collected to detect the DER and DLR, the 
precipitation was redispersed with purified water, 2 mL was 
withdrawn for particle size measurement and ZP analysis.
Peristaltic pump
Peristaltic pump
FA-CS solution
TPP solution
70% ehtanol solution
(Oil-A + FA-CS)
(pH = 5.4)
Water (pH = 3~4)
Add 1M NaOH
Stirring adequately for period of time
NHS-FA
Centrifugation and
freeze-drying
NHS-FA
FA-CS
Oli-A
FA-CS
Oil-A (in ethanol)
Oli-A
FA-Oli-CSNPs
Figure 1 schematic description of the preparation procedure of FA-Oli-csNPs.
Abbreviations: Oli-A, oligomycin-A; FA-cs, the folate-conjugated chitosan; TPP, 
sodium tripolyphosphate; FA-Oli-csNPs, folate-conjugated chitosan nanoparticles 
loading oligomycin-A; Nhs-folate, N-hydroxysuccinimide ester of folate.
The major factors affecting the particle size and drug 
loading efficiency of nanoparticles were the carrier concentra-
tion, the drug concentration, crosslinking agent concentration, 
mass ratio of carrier to crosslinking agent, and crosslinking 
time.29,30 So in this study, FA-Oli-CSNPs preparation proce-
dure was optimized by a five-factor, two-level factorial design 
(2-LFD), with FA-CS concentration (X1), Oli-A concentration 
(X2), mass ratio of FA-CS to TPP (X3), TPP concentration 
(X4), and crosslinking time (X5) as the independent variables 
(Table 1). The levels of those independent variables were 
based on preliminary trials. The MPS, DER, DLR and ZP of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the resulting FA-Oli-CSNPs were used as response variables. 
Each factor was studied at two levels; low level and high 
level, added center points. To analyze the factorial design, 
the original measurement units for the experimental factors 
(uncoded units) were transformed into coded units. The fac-
tor levels were coded as −1 (low), 0 (center) and +1 (high). 
MINITABTM (Minitab, State College, PA) release 15 statistical 
software was applied to generating and evaluating the statisti-
cal experimental design (Table 1) for gaining the optimum 
preparation condition. Five factors were used at two levels 
applying a 1/2 fraction factorial 25−1 Resolution V design and 
adding three center points resulting in 19 runs (Table 2).
Lyophilization
To further improve the chemical and physical stability of the 
final product, the resulting precipitate was freeze dried again 
after the final redispersion. Some amount of cryoprotectants 
(mannitol) were added to the final redispersed solution in 
10 mL glass vials before freeze drying if needed accord-
ing to the mass ration of mannitol: FA-Oli-CSNPs = 1:1 
(w/w). The mixture was firstly prefrozen in the refrigerator 
(−40°C) for 12 hours, subsequently lyophilized at −40°C for 
48 hours in a Gamma 2–20 apparatus (Christ, Osterode am 
Harz, Germany). Lastly, the FA-Oli-CSNPs, a kind of pale 
yellow powder, were obtained.
characterization of FA-Oli-csNPs
Determination of the Der and DLr of Oli-A
The dissociative Oli-A in the supernatant was examined by high 
performance liquid chromatography (HPLC). A Waters high 
performance liquid chromatograph (Waters Corporation, Mil-
ford, MA), consisting of a Waters 1525 Binary HPLC Pump, 
and a Waters 2489 UV/Visible Detector. The samples were 
chromatographed at 25°C by injecting of 5 µL of sample into a 
Diamonsil C18 column (250 mm × 4.6 mm, 5 µm; Dikma Tech-
nologies, Beijing, China). The mobile phase was composed of 
acetonitrile: deionized water = 80: 20 (v/v) at 1 mL ⋅ min−1. The 
UV/Visible detection wavelength was set to 226 nm. DLR and 
DER were determined by equations (1) and (2).
DLR (%) = (Oli-A(total mass) − Oli-A(dissociative mass))/ 
  FA-Oli-CSNPs(total mass) × 100%  (1)
Table 2 experimental design and results of the 2-LFD analysis
Run Variables Responses
X1 X2 X3 X4 X5 MPS  
(nm)
DER  
(%)
DLR  
(%)
ZP  
(mV)
1 8 0.5 10 0.5 4 435.6 8.4 0.5 22.2
2 4.25 5.25 5.25 1.75 2.25 298.3 27.8 25.5 28.7
3 8 10 10 3 4 478.1 8.5 9.6 46.2
4 0.5 10 0.5 0.5 0.5 419.1 6.6 56.5 20.1
5 0.5 10 10 3 0.5 82.1 5.3 51.4 20.3
6 0.5 0.5 0.5 3 0.5 700.4 5.5 5.2 14.0
7 8 0.5 0.5 0.5 0.5 184.4 23.0 1.4 21.5
8 8 10 0.5 3 0.5 74.1 8.0 9.0 25.6
9 8 0.5 0.5 3 4 185.7 30.2 1.9 35.2
10 4.25 5.25 5.25 1.75 2.25 251.7 24.9 23.6 26.9
11 4.25 5.25 5.25 1.75 2.25 275.0 26.4 24.5 27.8
12 8 10 10 0.5 0.5 513.2 3.4 4.0 33.7
13 8 0.5 10 3 0.5 993.1 5.6 0.4 47.2
14 0.5 0.5 10 3 4 126.1 1.6 1.6 21.7
15 0.5 10 0.5 3 4 150.2 6.2 55.2 26.8
16 0.5 0.5 10 0.5 0.5 301.0 2.6 2.6 20.9
17 0.5 10 10 0.5 4 526.0 34.4 87.3 18.4
18 8 10 0.5 0.5 4 241.3 0.5 0.7 28.4
19 0.5 0.5 0.5 0.5 4 502.5 16.5 14.2 14.1
Notes: FA-cs concentration (X1), Oli-A concentration (X2), mass ratio of FA-cs to TPP (X3), TPP concentration (X4), and crosslinking time (X5). 
Abbreviations: MPs, mean particle size; Der, drug entrapment rate; DLr, drug loading rate; ZP, zeta potential; FA-cs, folate-conjugated chitosan; Oli-A, oligomycin-A; 
2-LFD, two-level factorial design.
Table 1 Factors and their levels in 2-LFD analysis
Independent variables Symbol Coded levels
-1 0 1
FA-cs concentration (mg/mL) X1 0.5 4.25 8
Oli-A concentration (mg/mL) X2 0.5 5.25 10
Mass ratio of FA-cs to TPP X3 0.5 5.25 10
TPP concentration (mg/mL) X4 0.5 1.75 3
crosslinking time (h) X5 0.5 2.25 4
Abbreviations:  FA-cs,  folate-conjugated  chitosan;  Oli-A,  oligomycin-A;  TPP, 
sodium tripolyphosphate; 2-LFD, two-level factorial design.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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DER (%) = (Oli-A(total mass) − Oli-A(dissociative mass))/ 
  Oli-A(total mass) × 100%  (2)
MPs and ZP of FA-Oli-csNPs
The MPS and ZP of FA-Oli-CSNPs were determined by 
dynamic laser light scattering and a ZP analyzer (Zetapals, 
Brookhaven Instruments, Holtsville, NY), respectively. The 
samples were diluted with deionized water and measured at 
room temperature in triplicate. The multimodal size distri-
bution analysis method was adopted to calculate the MPS 
of samples.31
Morphology of FA-Oli-csNPs  
by a scanning electron microscopy
The morphology of the nanoparticles was observed by 
scanning electron microscopy (FEI Co, Eindhoven, The 
Netherlands). Prior to analysis, original Oli-A, the FA-CS, 
and FA-Oli-CSNPs powders were painted on the conductive 
adhesive, subsequently coated with gold (JFC 1200 fine 
coater, JEOL, Japan), and examined by scanning electron 
microscopy.
Drug release of FA-Oli-csNPs
Oli-A release from FA-Oli-CSNPs was determined in 
phosphate-buffered solution at 37°C. FA-Oli-CSNPs were 
dispersed in phosphate-buffered solution (5 mL), and placed 
in a dialysis bag (MWCO = 3500 Da). The end-sealed dialysis 
bag was immersed in a 250 mL beaker containing 200 mL 
release buffer, and the beaker was then placed in an incubator 
shaker at 37°C and 100 rpm. At predetermined time intervals, 
20 mL of the dialysis solution was withdrawn and replaced 
with an equal volume of fresh phosphate-buffered solution. 
In order to make a negative control, meanwhile, the release 
of Oli-A raw powder was also carried out according to the 
above method. The concentration of Oli-A in each collected 
release buffer sample was determined by HPLC as described 
earlier. The drug release studies were carried out in triplicate 
for each of the samples. The accumulative release percentage 
was calculated by using the following equations:
 C ′1 = C1
 C ′i+1 = Ci+1 − (V − Vi) × Ci/V  (3)
 Q i = Σ C′i × V/M × 100%  (4)
where Ci represents the Oli-A concentration of each sample 
withdrawn at predetermined time intervals, C′i represents the 
increase of the Oli-A concentration during each time interval, 
V represents the volume of the release buffer, Vi represents 
the volume of each withdrawn sample, M is the Oli-A loaded 
in the FA-Oli-CSNPs, and Qi is the accumulative release 
percentage at predetermined time point.
Results and discussions
The FTIr spectroscopy of Nhs-FA
Figure 2 shows the FTIR spectroscopy of FA and NHS-FA. 
NHS-FA presents two remarkable absorption peaks at 
1660 cm−1 due to the N–O bond, and 1700 cm−1 because of 
the C=O bond. This phenomenon proves that FA has been 
successfully transferred into NHS-FA. These results are 
accorded with Zhao’s report.32
The UV absorption spectroscopy  
of FA-cs
Figure 3 shows the UV absorption spectroscopy of CS, 
FA-CS and NHS-FA. CS has an extremely weak absorption 
peak at 300 nm, whereas NHS-FA has a strong absorption 
peak at 281 nm and a weak absorption peak at 343 nm. 
The absorption peaks of FA-CS at 281 nm and 343 nm 
confirmed the successful conjugation of NHS-FA with CS. 
  Furthermore, according to the calibration curve of the 
NHS-FA: y = 0.04580x − 0.01668, R2 = 0.9999 (x: NHS-FA 
concentration, µg/mL; y: absorption), then the amount of 
NHS-FA conjugation was 45.85 mg/g CS.
statistical analysis
Particle size plays a key role in determining the decentraliza-
tion of FA-Oli-CSNPs in vivo and easier access into cancer 
cells.33 The DLR is another important factor of drug delivery 
system. So the MPS and DLR of the resulting FA-Oli-CSNPs 
were used as response variables.
The results were analyzed by using MINITABTM release 
15 statistical software as shown in Table 2. The main effects and 
interactions between factors were determined. The effect of a 
factor is the change in response, here, MPS and DLR, produced 
by a change in the level of a factor, FA-CS concentration, Oli-A 
concentration, mass ratio of FA-CS to TPP, TPP concentration, 
and crosslinking time from lower to higher levels. The codified 
model employed for 22 factorial designs was
Response = A0 + A1X1 + A2X2 + A3X3 + A4X4 + A5X5 
  + A6X1X2 + A7X1X3 + A8X1X4 + A9X1X5 + A10X2X3 
  + A11X2X4 + A12X2X5 + A13X3X4 + A14X3X5  
  + A15X4X5    (5)
where A0 represents the global mean and Ai represents 
the regression coefficient corresponding to the main International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 2 The FTIR spectroscopy figure of NHS-FA compared with FA. 
Notes: Nhs-FA presents two remarkable absorption peaks at 1660 cm−1 due to the N–O bond, and at 1700 cm−1 because of the c=O bond. This phenomenon proves 
that FA has been successfully transferred into Nhs-FA.
Abbreviations: FA, Folate; Nhs-FA, N-hydroxysuccinimide ester of folate; Nhs, N-hydroxysuccinimide. 
  factor effects and interactions. The net effects,   regression 
  coefficients, standard errors, standardized effects (t) and 
P are shown in Table 3. The net effect is different between 
the responses of two levels (high and low level) of   factors; 
the regression coefficients are obtained by dividing the 
net effects by two. t-values are obtained by dividing 
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Figure 3 Determination of Nhs-FA conjugation with cs. 
Notes: (a) cs has an extremely weak absorption peak at 300 nm. (b) FA-cs has 
three absorption peaks, at 281 nm, 300 nm, and 343 nm, respectively. (c) Nhs-FA 
has a strong absorption peak at 281 nm and a weak absorption peak at 343 nm.
Abbreviations:  cs,  chitosan;  FA-cs,  the  folate-conjugated  chitosan;  Nhs-FA, 
N-hydroxysuccinimide ester of folate.
the   regression coefficients by standard error coefficient.33 
P-value is the probability value that is used to determine 
the effects in the model that are statistically significant. The 
significance of the data is judged by its P-value being closer 
to zero (0.00). For a 95% confidence level the P-value should 
be less than or equal to 0.05 for the effect to be statistically 
significant. The main effects represent deviations of the 
average between high and low levels for each one of them. 
When the effect of a factor is positive, responses (MPS 
and DLR) increase as the factor is changed from low to 
high levels. In contrast, if the effects are negative, a reduc-
tion in responses occurs for high level of the same factor. 
Substituting the regression coefficients in equation (5) we 
get the model equation relating the level of parameters and 
responses:
MPS (nm) = 369.55 + 18.64X1 − 59.05X2 + 62.35X3  
  − 20.83X4 − 38.88X5 − 2.46X1X2 + 154.47X1X3  
  + 65.39X1X4 − 14.15X1X5 + 27.00X2X3 − 93.56X2X4  
  + 77.26X2X5 + 8.78X3X4 − 1.60X3X5 − 74.82X4X5  (6)
DLR (%) = 18.84 − 15.41X1 + 15.38X2 + 0.83X3 − 2.06X4  
  + 2.52X5 − 12.99X1X2 − 0.64X1X3 + 3.84X1X4 − 2.79X1X5   
  + 3.04X2X3 − 0.85X2X4 + 1.45X2X5 − 1.87X3X4  
  + 2.56X3X5 − 2.25X4X5    (7)International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 3 Estimated effects and coefficients for MPS and DLR (coded units)
Term MPS DLR
Net  
effect
Regression  
coefficient
Standard  
error
Standardized  
effect (t)
P Net  
effect
Regression  
coefficient
Standard  
error
Standardized  
effect (t)
P
constant 369.55 5.819 63.51 0.0000 18.84 0.2488 75.75 0.0000
X1 37.27 18.64 5.819 3.20 0.0852 −30.82 −15.41 0.2488 −61.94 0.0003
X2 −118.10 −59.05 5.819 −10.15 0.0096 30.76 15.38 0.2488 61.84 0.0003
X3 124.70 62.35 5.819 10.72 0.0086 1.67 0.83 0.2488 3.35 0.0787
X4 −41.66 −20.83 5.819 −3.58 0.0699 −4.12 −2.06 0.2488 −8.27 0.0143
X5 −77.75 −38.88 5.819 −6.68 0.0217 5.05 2.53 0.2488 10.15 0.0096
X1 × X2 −4.92 −2.46 5.819 −0.42 0.7134 −25.97 −12.99 0.2488 −52.21 0.0004
X1 × X3 308.94 154.47 5.819 26.55 0.0014 −1.27 −0.64 0.2488 −2.56 0.1245
X1 × X4 130.78 65.39 5.819 11.24 0.0078 7.68 3.84 0.2488 15.43 0.0042
X1 × X5 −28.31 −14.15 5.819 −2.43 0.1355 −5.59 −2.79 0.2488 −11.23 0.0078
X2 × X3 53.99 27.00 5.819 4.64 0.0435 6.08 3.04 0.2488 12.22 0.0066
X2 × X4 −187.11 −93.56 5.819 −16.08 0.0038 −1.70 −0.85 0.2488 −3.14 0.0764
X2 × X5 154.52 77.26 5.819 13.28 0.0056 2.89 1.45 0.2488 5.82 0.0283
X3 × X4 17.56 8.78 5.819 1.51 0.2703 −3.75 −1.87 0.2488 −7.53 0.0172
X3 × X5 −3.20 −1.60 5.819 −0.27 0.8094 5.12 2.56 0.2488 10.30 0.0093
X4 × X5 −149.64 −74.82 5.819 −12.86 0.0060 −4.49 −2.25 0.2488 −9.03 0.0121
Notes: FA-cs concentration (X1), Oli-A concentration (X2), mass ratio of FA-cs to TPP (X3), TPP concentration (X4), and crosslinking time (X5). 
Abbreviations: MPs, mean particle size; DLr, drug loading rate.
student’s t-test
The Pareto chart (Figure 4) gives the relative importance of 
the individual and interaction effects. Student’s t-test was 
conducted to determine whether the calculated effects were 
significantly different from zero and these values for each 
effect are shown in the Pareto chart by horizontal columns. 
For a 95% confidence level and 16 degrees of freedom t-value 
is equal to 4.30. The vertical line in the chart indicates the 
minimum statistically significant effect magnitude for 95% 
confidence level.
Analysis of variance (ANOVA)
In Table 4 the sum of squares used to estimate the factors’ 
effects and F-ratios are shown. Since F0.05, 1, 2 = 18.5, all the 
effects with F value higher than 18.5 are significant. The 
effects are statistically significant when P-value, defined as 
the smallest level of significance leading to rejection of null 
hypothesis, is less than 0.05.
Based on the student’s t-test and F-test, few interaction 
effects which seem insignificant compared to other effects, were 
neglected and the net effects, regression coefficients, standard 
error and P-value were recalculated with remaining variables. 
Resultant values are shown in Table 5. Figure 5 shows the 
student’s t-test results. For the MPS, the magnitude of effects 
of each factor and their interactions were found to increase 
in the following order: FA-CS concentration × mass ratio of 
FA-CS to TPP . Oli-A concentration × TPP concentration . 
Oli-A concentration × crosslinking time . TPP concentration ×   
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Table 4 Analysis of variance for MPs and DLr using adjusted ss for tests
Source MPS DLR
Degrees of  
freedom
Sum of  
squares  
(SS)
Mean  
square  
(MS)
F P-value Degrees of  
freedom
Sum of  
squares 
(SS)
Mean  
square  
(MS)
F P-value
X1 1 5556.58 5556.58 10.26 0.0852 1 3798.87 3798.87 3837.12 0.0003
X2 1 55793.98 55793.98 102.99 0.0096 1 3785.94 3785.94 3824.05 0.0003
X3 1 62196.62 62196.62 114.81 0.0086 1 11.12 11.12 11.23 0.0787
X4 1 6942.64 6942.64 12.82 0.0699 1 67.73 67.73 68.41 0.0143
X5 1 24181.03 24181.03 44.64 0.0217 1 102.01 102.01 103.04 0.0096
X1 × X2 1 96.97 96.97 0.18 0.7134 1 2698.28 2698.28 2725.45 0.0004
X1 × X3 1 3.818e + 005 3.818e + 005 704.72 0.0014 1 6.50 6.50 6.57 0.1245
X1 × X4 1 68417.56 68417.56 126.30 0.0078 1 235.78 235.78 238.15 0.0042
X1 × X5 1 3204.98 3204.98 5.92 0.1355 1 124.88 124.88 126.14 0.0078
X2 × X3 1 11660.22 11660.22 21.52 0.0435 1 147.74 147.74 149.23 0.0066
X2 × X4 1 1.400e + 005 1.400e + 005 258.51 0.0038 1 11.49 11.49 11.61 0.0764
X2 × X5 1 95504.18 95504.18 176.30 0.0056 1 33.52 33.52 33.86 0.0283
X3 × X4 1 1233.94 1233.94 2.28 0.2703 1 56.18 56.18 56.74 0.0172
X3 × X5 1 40.86 40.86 0.075 0.8094 1 104.96 104.96 106.02 0.0093
X4 × X5 1 89567.02 89567.02 165.34 0.0060 1 80.64 80.64 81.45 0.0121
error 2 1083.45 541.73 2 1.98 0.99
Total 17 94728.03 17 11267.62
Notes: MPs: s = 23.28 r2 = 99.89%; r2
(adj) = 99.03%; F = adj ⋅ Msfactor/adj ⋅ Mserror
 DLr: s = 1.00 r2 = 99.98%; r2
(adj) = 99.85%; F = adj ⋅ Msfactor/adj ⋅ Mserror
.
Table 5 Estimated effects and coefficients for MPS and DLR – reduced model
Term MPS Term DLR
Net effect Regression  
coefficient
Standard  
error
P Net effect Regression  
coefficient
Standard  
error
P
constant 369.55 14.39 0.0000 constant 18.84 2.10 0.0000
X2 −118.10 −59.05 14.39 0.0027 X1 −30.82 −15.41 2.10 0.0000
X3 124.70 62.35 14.39 0.0019 X2 30.76 15.38 2.10 0.0000
X5 −77.75 −38.88 14.39 0.0243 X1 × X2 −25.97 −12.99 2.10 0.0000
X1 × X3 308.94 154.47 14.39 0.0000
X1 × X4 130.78 65.39 14.39 0.0014
X2 × X4 −187.11 −93.56 14.39 0.0001
X2 × X5 154.52 77.26 14.39 0.0005
X4 × X5 −149.64 −74.82 14.39 0.0006
Abbreviations: MPs, mean particle size; DLr, drug loading rate.
crosslinking time . FA-CS concentration × TPP concentration . 
mass ratio of FA-CS to TPP . Oli-A concentration .   crosslinking 
time. For the DLR, the increasing order of the effects is given 
by: FA-CS concentration . Oli-A concentration . FA-CS 
concentration × Oli-A concentration. Namely, reduced model 
equation with resultant coefficients was
MPS (nm) = 369.55 − 59.05X2 + 62.35X3 − 38.88X5  
  + 154.47X1X3 + 65.39X1X4 − 93.56X2X4  
  + 77.26X2X5 − 74.82X4X5   (8)
DLR (%) = 18.84 − 15.41X1 + 15.38X2 − 12.99X1X2  (9)
The reduced model ANOVA and F-test and were 
performed and results of ANOVA are given in Table 6.   
Lack of fit associated elimination of few factors was   
FMPS = 7.58. This was very much lower compared to tabulated 
value F0.05, 7, 2 = 19.4. Therefore, these factors did not have 
statistical significance. The residues should also be examined 
for normal distribution.
Main effects plot
The main effects plot is shown in Figure 6 for MPS and 
DLR. It indicates the relative strength of effects of various 
factors. A main effect is present when the mean response 
changes across the level of a factor. The sign of the main 
effect indicates the directions of the effect. It can be seen 
from Figure 6 that for MPS and DLR, the effect of Oli-A 
concentration was characterized by a greater degree International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 5 Pareto chart of the standardized effects for (A) MPs and (B) DLr – reduced model.
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Table 6 Analysis of variance for MPs and DLr – reduced model
Source MPS Source DLR
Degrees of  
freedom
Sum of 
squares  
(SS)
Mean  
square  
(MS)
F P-value Degrees of  
freedom
Sum of  
squares  
(SS)
Mean  
square  
(MS)
F P-value
X2 1 55793.98 55793.98 16.84 0.0027 X1 1 3798.87 3798.87 54.02 0.0000
X3 1 62196.62 62196.62 18.77 0.0019 X2 1 3785.94 3785.94 53.84 0.0000
X5 1 24181.03 24181.03 7.30 0.0243 X1 × X2 1 2698.28 2698.28 38.37 0.0000
X1 × X3 1 3.818e + 005 3.818e + 005 115.22 0.0000
X1 × X4 1 68417.56 68417.56 20.65 0.0014
X2 × X4 1 1.400e + 005 1.400e + 005 42.27 0.0001
X2 × X5 1 95504.18 95504.18 28.82 0.0005
X4 × X5 1 89567.02 89567.02 27.03 0.0006
residual  
error
9 29819.65 3313.29 residual  
error
14 984.54 70.32
Lack of fit 7 28736.20 4105.17 7.58 0.1215 Lack of fit 12 982.56 81.88 82.70 0.0120
Pure error 2 1083.45 541.73 Pure error 2 1.98 0.99
Total 18 9.699e + 005 Total 18 11349.74
Abbreviations: MPs, mean particle size; DLr, drug loading rate.
of departure from the   overall mean. The concentration 
of Oli-A had a negative effect on the MPS, decreasing 
with increasing concentration from 0.5 to 10 mg/mL. 
So, high concentration favors generating a smaller particle. 
However, the concentration of Oli-A had a positive effect on 
the DLR, increasing with increasing concentration from 0.5 to 
10 mg/mL. One possible reason is that FA-CS nanoparticles 
have more opportunity of loading the Oli-A with a high con-
centration. For MPS, the mass ratio of FA-CS to TPP showed 
a great positive effect, increasing with increasing the mass 
ratio from 0.5 to 10. So, low mass ratio favors forming a 
smaller particle. But crosslinking time had a slight negative 
effect. For DLR, the concentration of FA-CS was found to 
have a great negative effect with increasing concentration 
from 0.5 to 8 mg/mL. So, high DLR can be easily obtained 
at low concentration of FA-CS. All other factors showed a 
slight effect on the MPS and DLR.
Interaction effects plot
The interaction effects plots are shown in Figure 7 for MPS 
and DLR. The plots provide the mean response of two factors 
at all possible combinations of their settings. If the lines are 
not parallel, it is an indication of interaction between the two 
factors.34 For MPS, FA-CS concentration and mass ratio of 
FA-CS to TPP showed great antagonistic effects, under the 
condition of FA-CS concentration of 8.00 mg/mL, the MPS 
decreased with decreasing mass ratio of FA-CS to TPP from 
10 to 0.50. On the contrary, when FA-CS concentration of 
0.50 mg/mL was used, the MPS increased at decreasing mass 
ratio of FA-CS to TPP. Oli-A concentration and TPP concen-
tration, Oli-A concentration and crosslinking time, TPP con-
centration and crosslinking time, and FA-CS concentration 
and TPP concentration produced minor interaction effects on 
the MPS. For DLR, interaction effects between FA-CS con-
centration and Oli-A concentration showed that the DLR was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 6 Main effects plot for (A) MPs and (B) DLr.
Abbreviations: MPs, mean particle size; DLr, drug loading rate.
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Figure 7 Interaction plot for (A) MPs and (B) DLr.
Abbreviations: MPs, mean particle size; DLr, drug loading rate.
lower at Oli-A concentration of 0.50 mg/mL than at Oli-A 
concentration of 10.00 mg/mL. Other interactions showed 
no prominent features on two response variables.
Normal probability plot of residuals
One of the key assumptions for the statistical analysis of data 
from experiments is that the data come from a normal distri-
bution.34 The normality of the data can be checked by plotting 
a normal probability plot of the residuals. If the points on the 
plot fall fairly close to a straight line, then the data are normally 
distributed.34 The normal probability plot of MPS and DLR is 
shown in Figure 8. It can be seen that the points fall fairly close 
to the straight line. Therefore, the data from the experiments 
come from a normally distributed population.
Verification studies
Optimum values of the variables were obtained by mathemati-
cal analyses using MINITABTM release 15 statistical software 
and were based on the criterion of desirability. The optimized 
formulation was achieved with 0.5 mg/mL FA-CS, 10.00 
mg/mL Oli-A, 7.87 FA-CS/TPP (w/w), 2.55 mg/mL TPP, 
and 3.79 hours crosslinking time. The predicted responses 
were displayed with the MPS of 150.0 nm, DER of 18.4%, 
DLR of 62.6%, ZP of 23.6 mV and the desirability of 0.846. 
The FA-Oli-CSNPs with the MPS of 182.6, DER of 17.3%, 
DLR of 58.5%, and ZP of 24.6 mV were obtained by the 
verification experiments.
Morphology of FA-Oli-csNPs
Original Oli-A, FA-CS and FA-Oli-CSNPs were observed 
by scanning electron microscopy. Raw Oli-A particles are 
irregular lamelliform crystals (Figure 9A). Figure 9B shows 
the surface characteristic of FA-CS powder, which displays in 
the agglomeration state. Meanwhile, FA-Oli-CSNPs gained 
under optimum conditions were uniform and spherical with 
MPS of 182.6 nm (Figure 9C and D) approximately. The cor-International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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responding data about the quantitative changes of the particle 
size, namely, the particle size distributions of FA-Oli-CSNPs 
which were determined by dynamic laser light scattering are 
shown in Figure 10.
Drug release of FA-Oli-csNPs
The FA-Oli-CSNPs in the drug release experiment had a DER 
of 17.3% and a DLR of 58.5%, respectively. Figure 11 shows 
the release profiles of raw Oli and FA-Oli-CSNPs in vitro 
over 576 hours. The drug carrier system had a burst release 
in 12 hours and a slow release up to 576 hours, releasing 
approximately 10% and 90% of Oli-A, respectively. At the 
same time, the release rate of raw Oli was very slow under 
the same release conditions. These facts indicated FA-Oli-
CSNPs had a better solubility in water compared with raw 
Oli. The possible explanation for these discrepancies could be 
that Oli loaded in FA-Oli-CSNPs may exist in an amorphous 
formation, which can improve the solubility of compounds. 
The generally sustained and controlled release profile of Oli 
facilitates the application of nanoparticles for the delivery 
of anticancer drugs.34
Conclusion
The 2-LFD analysis has been successfully applied to opti-
mize the procedure for the preparation of FA-Oli-CSNPs. 
FA-Oli-CSNPs with a MPS of 182.6 nm was obtained under 
optimum conditions of FA-CS concentration of 0.5 mg/mL, 
Oli-A concentration of 10.00 mg/mL, mass ratio of FA-CS 
to TPP of 7.87 (w/w), TPP concentration of 2.55 mg/mL, 
and crosslinking time of 3.79 hours by MINITABTM release 
15 statistical software, respectively. Under these optimum 
conditions, DER, DLR, and ZP were 17.3%, 58.5%, and 
24.6 mV , respectively. The amount of FA conjugation was 
45.9 mg/g CS. The FA-Oli-CSNPs showed sustained-release 
characteristics for 576 hours in vitro. Oli-A has a definite 
effect on CML. CS nanoparticles with a particle size of less 
than 200 nm have passive targeting to the cancer cell. The 
drug delivery systems conjugating FA have active targeting to 
the CML cell with high expression of FA surface receptors.35 
So, we can infer that the FA-Oli-CSNPs should have a good 
therapeutic effect in vitro and in vivo.
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